Welcome to our next molecule of the month 2024 - DOTA-RGDfK dimer acetate
The Integrin αvß3 is one of the earliest studied integrins and was found to be expressed in several tumors e.g. glioma, lung cancer brain metastases, prostate cancer or pancreatic cancer. The αvβ3 integrin receptors can be targeted by peptides containing the RGD sequence. For example, Dota-RGD-Dimer Acetate, which can be used both as a potential therapeutic agent [1] and as a diagnostic agent [2]. ABX has several RGD peptides for labelling with radiometals in its catalogue (e.g. ABX prod. no. 9863 for the corresponding monomer or 9804 for the corresponding NODAGA-RGD Dimer).
Learn more about the related products and send us your request!
DOTA-RGDfK dimer acetate
[1] Myrna Luna-Gutiérrez et al. 177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing α(ν)β(3) integrins. J. Label Compd. Radiopharm. 2013, 55, 140-148.
[2] Dana Niculae et al. Development of NOTA/DOTA cyclo-RGD dimers labelled with Ga-68 for cancer diagnosis and therapy follow-up. J. Nucl. Med. 2013, 54, (supplement 2) 1131.
Learn more about the related products and send us your request!
DOTA-RGDfK dimer acetate
[1] Myrna Luna-Gutiérrez et al. 177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing α(ν)β(3) integrins. J. Label Compd. Radiopharm. 2013, 55, 140-148.
[2] Dana Niculae et al. Development of NOTA/DOTA cyclo-RGD dimers labelled with Ga-68 for cancer diagnosis and therapy follow-up. J. Nucl. Med. 2013, 54, (supplement 2) 1131.